Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
暂无分享,去创建一个
M. Gail | W. McCaskill-Stevens | G. Anderson | B. Graubard | J. Costantino | A. Freedman | V. Vogel | Binbing Yu
[1] Joseph P. Costantino,et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.
[2] H. Nelson,et al. Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer , 2009, Annals of Internal Medicine.
[3] J. Cuzick,et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Cuzick,et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. , 2009, Journal of oncology practice.
[5] Melissa Bondy,et al. Projecting individualized absolute invasive breast cancer risk in African American women. , 2007, Journal of the National Cancer Institute.
[6] S. Márquez-Calderón,et al. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: A systematic review , 2007, International journal of cancer.
[7] J. Cuzick,et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.
[8] T. Powles,et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.
[9] E. Barrett-Connor,et al. Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.
[10] Norman Wolmark,et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.
[11] John Robbins,et al. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.
[12] R. J. Cersosimo. Tamoxifen for Prevention of Breast Cancer , 2003, The Annals of pharmacotherapy.
[13] M Baum,et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.
[14] Gordon Guyatt,et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. , 2002, Endocrine reviews.
[15] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[16] M H Gail,et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.
[17] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[18] J Benichou,et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.
[19] C C Glüer,et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.
[20] P. Boyle,et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.
[21] T. Powles,et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.
[22] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[23] JoAnn E. Manson,et al. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.